FDA Should Create Separate Division To Review Drug-Induced Liver Toxicity – Consultant
This article was originally published in The Pink Sheet Daily
The new division would allow for standardized evaluation of drugs with evidence of hepatoxicity, consultant Thomas Garvey says. He also recommends strengthening post-marketing reporting requirements.
You may also be interested in...
Draft guidance establishes targeted education and outreach, reminder systems, and performance-linked access systems as three categories of risk minimization tools. The draft drops a concept paper proposal that would have grouped drugs into one of four tiers of risk management programs.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.